Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?

摘要: Cancer treatments are rapidly changing. Curative treatment for oesophageal adenocarcinoma currently involves surgery and cytotoxic chemotherapy or chemoradiotherapy. Outcomes both regimes generally poor as a result of tumor recurrence. We have reviewed the key signalling pathways associated with adenocarcinomas discussed recent trials novel agents that attempt to target these pathways. There many underway aim improving survival in cancer. Currently, phase 2 3 focused on MAP kinase inhibition, either through inhibition growth factor receptors signal transducer proteins. In order avoid resistance, it appears be clear targeted therapy will needed combat multiple operation adenocarcinomas. This may achievable future advent gene signatures combinatorial approach.